Typewriter Therapeutics emerged from stealth with a $56 million Series A financing, focusing on RNA-based gene therapies and in vivo CAR T strategies for cancer, autoimmune disease, and severe genetic disorders. The announcement positions the company to build its pipeline around delivering CAR components or related genetic instructions inside the body. While early-stage details were limited in the report, the funding size signals investor confidence in in vivo approaches that aim to bypass patient-specific cell manufacturing. The company’s near-term priorities will likely include target validation, payload design, and delivery optimization to support later preclinical packages. In a sector still balancing manufacturing complexity with clinical momentum, Typewriter’s launch adds to the growing field of “platform” companies attempting to systematize in vivo immunotherapy development. The Series A also adds competitive pressure for delivery-focused and RNA gene-therapy sponsors.